Evolutionary Genomics, Inc. (FNAM)

USD 0.0

(0.0%)

Long Term Debt Summary of Evolutionary Genomics, Inc.

  • Evolutionary Genomics, Inc.'s latest annual long term debt in 2022 was 3.74 Million USD , down 0.0% from previous year.
  • Evolutionary Genomics, Inc.'s latest quarterly long term debt in 2023 Q3 was - USD , down 0.0% from previous quarter.
  • Evolutionary Genomics, Inc. reported annual long term debt of 3.74 Million USD in 2021, up 66.7% from previous year.
  • Evolutionary Genomics, Inc. reported annual long term debt of 2.24 Million USD in 2020, down 0.0% from previous year.
  • Evolutionary Genomics, Inc. reported quarterly long term debt of - USD for 2023 Q1, down -100.0% from previous quarter.
  • Evolutionary Genomics, Inc. reported quarterly long term debt of - USD for 2023 Q3, down 0.0% from previous quarter.

Annual Long Term Debt Chart of Evolutionary Genomics, Inc. (2022 - 2009)

Historical Annual Long Term Debt of Evolutionary Genomics, Inc. (2022 - 2009)

Year Long Term Debt Long Term Debt Growth
2022 3.74 Million USD 0.0%
2021 3.74 Million USD 66.7%
2020 2.24 Million USD 0.0%
2019 - USD 0.0%
2018 - USD 0.0%
2017 - USD 0.0%
2016 - USD 0.0%
2015 - USD 0.0%
2014 - USD 0.0%
2013 - USD 0.0%
2012 - USD 0.0%
2011 - USD 0.0%
2010 - USD 0.0%
2009 - USD 0.0%

Peer Long Term Debt Comparison of Evolutionary Genomics, Inc.

Name Long Term Debt Long Term Debt Difference
America Great Health 1.12 Million USD -233.329%
Gene Biotherapeutics, Inc. - USD -Infinity%
Innovation1 Biotech Inc. 218.99 Thousand USD -1609.481%
Point of Care Nano-Technology, Inc. - USD -Infinity%
Vicapsys Life Sciences, Inc. - USD -Infinity%